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Abstract
Background: Breast cancer is the first cause of cancer death among women and its incidence
doubled in the last two decades. Several approaches for the treatment of these cancers have been
developed. The axillary lymph node dissection (ALND) leads to numerous morbidity complications
and is now advantageously replaced by the dissection and the biopsy of the sentinel lymph node.
Although this approach has strong advantages, it has its own limitations which are manipulation of
radioactive products and possible anaphylactic reactions to the dye. As recently proposed, these
limitations could in principle be by-passed if semiconductor nanoparticles (quantum dots or QDs)
were used as fluorescent contrast agents for the in vivo imaging of SLN. QDs are fluorescent
nanoparticles with unique optical properties like strong resistance to photobleaching, size
dependent emission wavelength, large molar extinction coefficient, and good quantum yield.
Methods: CdSe/ZnS core/shell QDs emitting around 655 nm were used in our studies. 20 µL of
1 µM (20 pmol) QDs solution were injected subcutaneously in the anterior paw of healthy nude
mice and the axillary lymph node (ALN) was identified visually after injection of a blue dye. In vivo
fluorescence spectroscopy was performed on ALN before the mice were sacrificed at 5, 15, 30, 60
min and 24 h after QDs injection. ALN and all other organs were removed, cryosectioned and
observed in fluorescence microscopy. The organs were then chemically made soluble to extract
QDs. Plasmatic, urinary and fecal fluorescence levels were measured.
Results: QDs were detected in ALN as soon as 5 min and up to 24 h after the injection. The
maximum amount of QDs in the ALN was detected 60 min after the injection and corresponds to
2.42% of the injected dose. Most of the injected QDs remained at the injection site. No QDs were
detected in other tissues, plasma, urine and feces.
Conclusion: Effective and rapid (few minutes) detection of sentinel lymph node using fluorescent
imaging of quantum dots was demonstrated. This work was done using very low doses of injected
QDs and the detection was done using a minimally invasive method.
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Background
Breast cancer is the first cause of cancer death with a 100%
rising in incidence from 1980 to 2000 and 35% growth in
mortality [1]. Axillary lymph node dissection (ALND) is
the standard surgical treatment in breast cancer patients.
It consists in whole lymphatic axillary chain removal with
the aim to reveal presence of metastases by histology anal-
yses. However, this procedure leads to numerous morbid-
ity problems such as pain, lymphocel, restriction of arm
motion, chronic lymphedema, paresthesia, and, as a con-
sequence, deterioration of life quality. For these reasons,
an alternative treatment consisting in the sentinel lymph
node (SLN) biopsy has been met with enthusiasm by cli-
nicians. The SLN is the first node in the lymphatic basin
into which drains the primary tumour [2]. As a result, axil-
lary lymph node status is the most important prognostic
factor and a determinant in the choice of therapy [3]. SLN
biopsy consists in 99mTc-radiolabeled sulfur colloid injec-
tion the day before surgery in peritumoral or periareolar
area [4] followed by lymphoscintigraphy to identify radi-
oactive lymph node(s). During the surgery, a blue dye is
injected in the same way and SLN is thus identified as blue
and hot lymph node, one of these criterions only is not
sufficient for a successful SLN identification [5]. Despite
the significant improvement of SLN biopsy over ALDN,
the problems related to potential radiation hazards along
with an extra cost of the radioisotope, to allergic reactions
after blue dye injection and the overall procedure dura-
tion are limiting factors for this technique [6]. The ideal
method should be sensitive, accurate, rapid, non invasive,
non radioactive, and potentially usable in a laparoscopic
setting for gastrointestinal tumors [7]. None of the current
methods fulfills all of these criteria. Lymphatic mapping
with blue dye results in a high rate of false-positive nodes
because the small dye particles can readily diffuse through
the true SLN and traverse multiple nodes [8]. Addition-
ally, blue dye has poor tissue contrast and is difficult to
detect in deep, dark anatomical regions such as the abdo-
men. Although the use of radioisotope tracers has
improved the detection rate and accuracy of SLN map-
ping, the high radioactivity of the primary injection site
can interfere with intraoperative in vivo detection of
nearby nodes [3]. Additionally, if radioisotopes are
injected during surgery, the time period required for the
tracer to migrate to the SLN may delay the operative pro-
cedure. Conversely, preoperative injection of the radiocol-
loid tracer often necessitates anywhere from 2 to 16 hours
before surgery. This is difficult, if not impossible, to
accomplish and is applicable only in endoscopically
accessible regions of the colon and stomach [7].
Quantum dots (QDs) are fluorescent inorganic nanome-
ter sized crystals with remarkable unique optical and elec-
tronic properties. They are composed of a fluorescent core
of semiconductor heavy metals. In order to limit their
potentially toxic effects due to the release of Cd2+ or Se2-
ions in case of oxidation of the core (by ultraviolet (UV)
light or oxygen) and to passivate the defects on its surface,
this core is encapsulated in a shell of organic material,
polymeric or lipid-based layers then coat the shell. They
have a good quantum yield and absorption cross-section
such that single QD fluorescence imaging is possible in
cells. QDs have been already applied to visualize SLN in
gastrointestinal tract [7], pleural space [9], lung area [10],
oesophageal area [11], skin [12] and axilla [13] using
infrared light. Recently, red and infra-red emitting QDs
were imaged in inguinal and axillary lymph nodes in
tumor bearing mice already 3 min after local injection
[14]. Major difficulty in using QDs in vivo is their
unknown potential toxicity. However, it has been demon-
strated that the injection of 2.109 QDs/cell in xenopus
embryos unaltered their phenotype and health [15] and
that QDs triggered apoptosis via reactive oxygen species
(ROS) production only when they are not coated with
ZnS [16,17]. QDs toxicity study is ultimately related to the
investigation of their biodistribution in pre-clinical mod-
els. Currently, only few detailed works on QDs biodistri-
bution in rodents have been realized [18-20].
The primary objective of this work was to detect and quan-
tify at different times after the injection the selective accu-
mulation of carboxyl coated QDs in axillary draining
lymph nodes. Secondly, we assessed the biodistribution
of QDs in different tissues by fluorescence microscopy
and chemical extraction procedures. The rationale for the
choice of carboxyl coating was based on the observation
that negative charge confine to QDs certain selectivity to
reticuloendothelial system (RES) [21] along with the
excellent retention in lymph nodes [22]. Red emitting 655
nm QDs were considered in this study because of their
better fluorescence quantum yield compared to that of IR
QDs (fluorescence quantum yield) allowing better quan-
tification with regard to detection level of spectroscopic
tools.
Methods
Animals
Eight to twelve weeks old female athymic Fox nude mice
(Hsd:Athymic Nude-Foxn1nu) (Harlan, Gannat, France)
weighing from 15 to 25 g were used in these experiments.
Mice were kept in 12 h light/dark cycle and had access to
food and water ad libitum until 24 h before the experimen-
tation. Starvation was performed 24 h before manipula-
tion because of possible food fluorescence interference at
the emission wavelength of the QDs. Animal procedures
were performed in compliance with institutional and
national guidelines. Six groups of animals, each com-
posed of 5 mice, were used for lymphotropism and bio-
distribution studies: one control group who received only
phosphate buffer saline (PBS), and five experimentalBMC Cancer 2008, 8:111 http://www.biomedcentral.com/1471-2407/8/111
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groups injected with QDs. All experiments were per-
formed under anesthetic using intraperitoneal injection of
0.01 mL/g of body weight of a solution containing 8 mg/
mL ketamine (Ketalar®, Panpharma, Fougères, France)
and 0.8 mg/mL xylazine (Rompun®, Bayer Pharma,
Puteaux, France).
Quantum Dots and administration
Quantum Dots (QDs) with a maximum emission peaks at
655 nm were purchased from Quantum Dot Corporation
(Qdot® 655 ITK™ carboxyl). These QDs are described by
the manufacturer as CdSe/ZnS core/shell nanoparticles
coated with a polymer having an excess of carboxylic acid
groups. Their characteristics include : 16 nm diameter,
94% size monodispersity, extinction coefficient of
800.000 M-1 cm-1 at 638 nm, and a fluorescence quantum
yield of 80% with a full width at half maximum of 28 nm.
Twenty µL of a 1 µM (20 pmol) QDs solution was injected
subcutaneously in the distal part of the right anterior paw,
together with 20 µL of 1% patent V blue 2.5%® (Guerbet,
Roissy CdG, France) as reference method. The paw was
kneaded to allow migration of QDs and blue dye. Mice
were sacrificed at 5, 15, 30, 60 min and 24 h after injection
by cervical dislocation.
In vivo fluorescence spectroscopy
In situ quantification of fluorescence was carried out using
laser-induced fluorescence (LIF) as described previously
[23]. Two optical fibers were held in direct contact with
the axillary lymph node (ALN). One fiber was coupled to
a krypton laser (410 nm) to ensure excitation. The second
fiber was coupled to a spectrograph (USB2000, Ocean
Optics, Dunedin, FL, USA) and a CCD captor transferred
to a PC for a fluorescence spectrum acquisition. The fluo-
rescence of the rhodamine B (1 µM in water) was used for
the calibration of the excitation light intensity. Fluores-
cence measurements were performed at three different
sites: on the skin away from injection site (belly skin), on
the LN through the skin and after skin removal in vivo. The
measurements were performed at 5, 15, 30, 60 min and
24 h after QDs injection. Measurements in control group
were performed at 24 h after PBS injection.
Fluorescence microscopy
After sacrifice, ALN, bladder, belly skin, spleen, kidney,
heart, lung, brain, stomach, liver and intestine were
removed and frozen at -80°C. Six micron frozen sections
of all organs were prepared after embedding in Tissue Tek®
(Sakura Finetek, Torrance, CA, USA). Fluorescence was
observed under an upright epifluorescence microscope
(AX-70 Provis, Olympus, Rungis, France) equipped with a
100 W mercury vapor lamp and a Peltier cooled CCD
camera (DP50, Olympus). The filter set consisted of a
400–440 nm band pass excitation filter associated with a
570 nm dichroic mirror and a 590 nm long pass filter. Flu-
orescence images were recorded using × 40 enlargement.
Quantitative determination of QDs
Organs were removed at time points indicated above,
weighed and made soluble in Solvable® (Perkin-Elmer,
Courtaboeuf, France). Solvable® was added proportion-
ally to organ weight (0.5 mL for a weight ≤ 50 mg, 1.0 mL
for a weight ≤ 200 mg and 1.5 mL for a weight ≤ 300 mg).
Organs were next incubated at 50°C until the samples
become soluble. A sample of each organ, except ALN and
bladder, was 40 times diluted in PBS and analyzed by
spectrofluorometry (Xenius, SAFAS, Monaco). An excita-
tion wavelength of 350 nm was used and the spectra were
collected between 600 and 690 nm. In a parallel set of
experiments, a calibration curve for each organ was estab-
lished while adding a known concentration of QDs to tis-
sue of interest and the fluorescence of the resulting
mixture was measured. Blood samples were collected
through cardiac puncture in heparinized and cooled tubes
5, 15, 30, 60 min and 24 h after QDs injection. Samples
were centrifuged at 3000×g for 10 min at 4°C. Plasma was
recovered, ten fold diluted and its fluorescence emission
under 450 nm excitation was measured using a spec-
trofluorometer (PerkinElmer LS50B, Courtaboeuf,
France). Urine and feces were collected daily during 2
days. Urine was 10 fold diluted, feces were made soluble
by Solvable® at 50°C and the fluorescence of both samples
was measured by spectrofluorometry (PerkinElmer
LS50B, Courtaboeuf, France) using a 350 nm excitation
wavelength.
Statistical analyses
The non-parametric test of Kruskall-Wallis was employed
to establish statistical significance. Mann-Whitney's U test
was subsequently used to compare two by two the groups
for which Kruskall-Wallis test was significant. All analyses
were performed on StatView® 5.0 software (Abacus con-
cepts, Berkeley, CA, USA) and all results values were
expressed by mean ± SEM (standard error of the mean), *
for P < 0.05 and ** for P < 0.01 compared to the control
group.
Results
Chemical extraction of QDs in axillary lymph node
Chemical extraction (Figure 1) of QDs in ALN revealed
the presence of 40 ± 12 pmol/g tissue in the ALN already
5 min after injection with a maximum of 209 ± 75 pmol/
g at 60 min after injection. Approximately a 4 fold fluores-
cence decrease was observed 24 h post-injection (47 ± 8
pmol/g) (P = 0.0088 for all groups). The percentage of
migrated QDs (Table 1) has been derived from Figure 1 by
calculating the ratio between the quantity of QDs in ALN
and the quantity of QDs at the injection (20 pmol). The
amount of QDs that migrated to the lymph node 60 minBMC Cancer 2008, 8:111 http://www.biomedcentral.com/1471-2407/8/111
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after the injection corresponds to 2.42% of the total
injected dose.
Fluorescence microscopy experiments
Figure 2 displays typical transmission and fluorescence
images of lymph nodes frozen sections in control ALN 5
min post-injection. Compared to the background fluores-
cence, the QDs treated lymph nodes exhibited a distinct
fluorescence in the trabecular and medullar sinuses (Fig-
ure 2, panel D). It should be noted that QDs fluorescence
detected in other examined organs (brain, bladder,
spleen, kidneys, heart, lungs, liver and intestine) was not
different (data not shown) from the autofluorescence
observed in a control lymph node (Figure 2, panel B).
QDs biodistribution in organs
Mice were injected with QDs, sacrificed 24 h after injec-
tion, all organs were removed and subjected to chemical
extraction. Figure 3 exhibits typical fluorescence spectra of
ALN, liver, lungs, spleen and kidneys. Except for the ALN,
no fluorescence peak at 655 nm was detected in the sam-
ples. Similar results were found for all time points (5, 15,
30, 60 min and 24 h) and all other tested organs, namely
brain, bladder, heart, intestine and skin (data not shown).
In a parallel set of experiments we have computed the
detection limit of the QDs concentration for each organ
using the fluorescence calibration curve. The detection
limit ranges from 0.72 pmol of QDs per g of tissue for the
bladder to 4.2 pmol/g of tissue for the liver (Table 2). This
suggests that the QDs signal in each organ is below the
Table 1: Percentage of QDs injected quantity detected in ALN by spectrofluorometry after chemical extraction.
5 min 15 min 30 min 60 min 24 h
0.47 ± 0.21% ** 0.27 ± 0.10% ** 1.00 ± 0.47% ** 2.42 ± 0.57% ** 1.24 ± 0.34% **
20 pmol were injected subcutaneously in the anterior paw of nude mice. After sacrifice at 5 min, 15 min, 30 min, 60 min and 24 h after injection, 
ALN was removed, solubilized and the fluorescence of the solution was measured and is expressed as a percentage of the injected doze. Values 
were expressed by mean ± SEM, values marked with asterisk were significantly different from control (P < 0.01). QDs: Quantum Dots; ALN: 
Axillary Lymph Node
Concentration of QDs (pmol/g) detected in ALN Figure 1
Concentration of QDs (pmol/g) detected in ALN. 20 pmol were injected subcutaneously in the distal part of the right 
anterior paw of nude mice. Mice were sacrificed at 5, 15, 30, 60 min and 24 h after injection. Concentration of QDs (pmol/g) 
was detected in ALN by spectrofluorometry after chemical extraction. Error bars represent SEM, values marked with asterisk 
were significantly different from control (P < 0.01). ALN: Axillary Lymph Node; QDs: Quantum Dots.
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detection thresholds. Extraction of the QDs in the urine
and feces was also performed at 48 h post-injection and
no fluorescence was detected in the sample pointing out
that QDs were not excreted from the body.
Kinetic of QDs accumulation in lymph nodes by LIF
The in vivo kinetics of the QD accumulation in the lymph
nodes were studied using fluorescence measurements per-
formed on the animal with a optical fiber spectrofluorom-
eter. No significant fluorescence difference was found
concerning the skin aside from the injection point after
QDs administration, suggesting that QDs do not migrate
into the skin. While QDs emission in the ALN was not
detected across the skin, a clear signal was evidenced after
incision of the skin and measurement on the ALN (called
ALN in vivo) (Figure 4) (P = 0.0209 for 5, 15, 30 min; P =
0.0339 for 60 min and P = 0.0143 for 24 h). A very strong
fluorescence signal was observed as early as 5 min post-
injection (1.79 ± 0.97). In vivo measured animals exhib-
ited a persistent fluorescence till 60 min observation (3.78
± 1.36). Except of 30 min time point, we observed a grad-
ual increase in fluorescence till 60 min. This time point
(30 min) is likely suffered from a complexity of optical
measurements. A considerable fluorescence decrease was
observed at 24 h post-injection (1.40 ± 0.46). Measure-
ments performed at the injection site showed very high
intensity peak (ca. 4000 a.u.) with no marked difference
in intensity during observation time, till 24 h (data not
shown). This suggested that the majority of the injected
quantity remained at the injection site.
Discussion
In vivo biodistribution studies of QDs are sparse and deal
mostly with intravenously (IV) injected QDs. The general
consensus is that QDs distribution depends on their phys-
icochemical properties and in particular, size and coating.
Tracer particle size has an important effect on migration
time in SLN mapping. Particles < 5 nm diffuse into blood,
those between 5 to 10 nm can migrate through nodal tis-
sue and result in false-positive results, and those > 1000
nm largely remain at the injection site. Consequently, we
choose QDs with a diameter of 16 nm, since a size range
between 15 and 20 nm is optimal to enable the QDs to
travel through the lymph channels and be trapped by SLN
[9,12]. Concerning coating, we choose carboxyl coated
QDs. The carboxyl groups present the property to be neg-
atively charged and therefore display rapid uptake in lym-
phatics and excellent retention in lymph nodes
[12,21,24].
To our knowledge, a single biodistribution study was car-
ried out after non-IV administration of QDs. Gopee et al.
[19] investigated the distribution in healthy mice of 48
pmol intradermally (ID) injected QDs with a diameter of
37 nm and PEG coating. The authors did not find any
QDs in lymph nodes until 12 h after injection, whereas we
could detect them already 5 minutes following the injec-
tion (Figure 1). An early detection (3 min) of QDs
traveling toward inguinal nodes was observed after intra-
tumoral injection of red emitting QDs at concentrations
similar to ours [14]. However this observation was not fol-
Transmission and fluorescence microscopy images of ALN  frozen sections Figure 2
Transmission and fluorescence microscopy images of 
ALN frozen sections. Nude mice were injected with 20 
pmol of QDs or PBS (control) in the distal part of the right 
anterior paw. Panels A, B: transmission and fluorescence 
images of ALN control; Panels C, D: transmission and fluo-
rescence images of ALN 5 min after QDs injection (40 × 
enlargement). ALN: Axillary Lymph Node; QDs: Quantum 
Dots.
Table 2: Detection limit of QDs (pmol/g) in each organ after chemical extraction.
Tissue ALN Liver Kidneys Spleen Lungs Heart Intestine Brain Bladder Skin
Detection limit (pmol/g) 2.49 4.20 2.20 2.76 2.78 3.98 2.67 2.69 0.72 1.77
QDs: Quantum Dots; ALN: Axillary Lymph NodeBMC Cancer 2008, 8:111 http://www.biomedcentral.com/1471-2407/8/111
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lowed by biodistribution investigations. QDs Fluores-
cence increases with time to reach a maximum at 60 min
after the injection. The calculated percentages of the
injected dose (2.42% at 60 min and 1.24% at 24 h) (Table
1) were comparable with those of Kim et al. [13] and
Gopee et al. [19] who found 2–4% and 1.07% respectively
in the SLN. We observed a 4 fold decrease of QDs concen-
tration in ALN from 60 min to 24 h post-injection (Figure
1). We also noted a strong fluorescence of QDs at the
injection site. This observation is consistent with the study
of Gopee and co-workers [19] who found 60% of cad-
mium retention at the injection site. We further under-
took the study of the biodistribution of QDs in the organs.
No fluorescence peak was observed after chemical extrac-
tion of Qdot® 655 ITK™ carboxyl in liver, kidneys, spleen,
lungs, heart, intestine, brain, bladder, and skin (Figure 3).
This points out that we are below the calculated concen-
tration limit (Table 2), even if the latter is as low as around
2.5 pmol/g of tissue. The lower detection threshold
observed for pigmented organs such as liver and heart was
expected (Table 2) since the fluorescence detection
method employed in our study is very sensitive to the
absorption properties of the sample. In contrast to our
results, the previous QDs biodistribution studies all evi-
denced the presence of QDs in the liver and also to a
minor extent in spleen and kidneys [18,19]. The plausible
explanation could be provided by the difference in the site
of injection. Gopee et al. [19] injected QDs ID in the dor-
sal flank and found 24 h after injection 6.40% of the ini-
tial dose in liver and a small amount in kidneys (0.51%)
and spleen (0.18%). We have administrated QDs subcu-
taneously in the paw. ID injection of QDs in the flank
drains differently from the SC injected QDs [25] because
of the anatomical differences in lymphatic network of the
two regions. Likewise, when intradermal injection is per-
formed on the back, direct lymphatic drainage to retro-
peritoneal and paravertebral nodes can occur before the
injected product is distributed throughout the body [26].
When injection is performed in the paw, the first lymph
node that receives direct lymphatic drainage is always in
the axillary area. QDs are unlikely to be excreted from the
body, neither by urine nor by feces in the time span of 48
h. This observation is in agreement with previous work
[18] demonstrating the absence of QDs in urine and feces
during ten days. Theses results are explained by the dra-
matic reduction of renal filtration for QDs with a hydro-
dynamic diameter higher than 3.5 nm and with negative
charges [27]. Taken as a whole, the decline in QDs con-
Normalised fluorescence emission spectra of organs extracts Figure 3
Normalised fluorescence emission spectra of organs extracts. ALN, spleen, kidneys, lungs, liver were chemically solu-
bilised 24 h after subcutaneous injection of 20 pmol of QDs. Fluorescence spectra of the extracts were then recorded. Error 
bars represent SEM. ALN: Axillary Lymph Node; QDs: Quantum Dots.
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centration 24 h post-injection could not be attributed to
the elimination and/or migration of QDs to different
organs. Assuming very strong retention in SLN, we
hypothesize that QDs may diffuse in the second lymph
node of the chain. This supposition is consistent with the
fluorescence distribution pattern of QDs in SLN (Figure
2). Indeed QDs fluorescence is extended till medulla
sinus, thus rending possible the migration to the distal
lymph node through the lymph channels. The interaction
of QDs with serum should also be addressed. We did not
perform studies on the interaction of carboxyl QDs with
serum proteins, however, as it was shown recently anionic
or cationic charged QDs were associated with an increase
of the hydrodynamic diameter after incubation with
serum [20]. Moreover, the intensity of fluorescence of
QDs increases in the presence of BSA [28] or hemoglobin
[29].
Spectrofluorometry using an optical fiber is a non-inva-
sive procedure for the detection of fluorescent tracers. The
results of our study demonstrate that despite the incapac-
ity to detect QDs directly through the skin, LIF measure-
ments allow the detection of QDs in ALN after skin
incision with a profile similar to chemical extraction (Fig-
ure 4). However, non-invasive measurements are fre-
quently suffering from significant variations of
measurements, related to light diffusion and scattering.
Further, actually, our work is a preliminary step to use of
NIR emitting QDs which we expect the detection of QDs
through the skin without any incision. In the future, the
non-invasive measurements could be achieved by modu-
lating an excitation wavelength and using NIR emitting
QDs. The excitation wavelength in our study was set to
410 nm. Using an excitation at larger wavelengths should
result in less skin absorption and scattering, and should
make deep tissue imaging possible. Detection of QDs
with optical fiber spectroscopy opens perspectives for the
utilization of this technique in operation theatre, since it
can provide a rapid and reliable QDs detection immedi-
ately after SLN excision. A limitation to the clinical use of
QDs for SLN mapping is their potential toxicity [30].
However, because most of the injected dose is eliminated
Normalised 655 nm fluorescence intensity detected by LIF with optical fiber spectrofluorometer Figure 4
Normalised 655 nm fluorescence intensity detected by LIF with optical fiber spectrofluorometer. 20 pmol of 
QDs or PBS (control mice) were injected subcutaneously in the distal part of the anterior paw of a nude mice. Kinetics of LIF 
measurements were done on skin after QDs injection, ALN with skin and in vivo for control, 5 min, 15 min, 30 min, 60 min and 
24 h. Error bars represent SEM, values marked with asterisk were significantly different from control (* for P < 0.05). QDs: 
Quantum Dots; LIF: Laser-Induced Fluorescence; ALN: Axillary Lymph Node.
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by removal of the injection site and nodal tissue, the even-
tual toxicity may be negligible. Furthermore, to avoid tox-
icity caused by biodegradation of QDs and exposition of
core metal ions, QDs with non-heavy metal cores (such as
indium) would be developed along with ameliorations of
surface chemistry [31].
Conclusion
In this study we demonstrated that 655 nm emitting QDs
with carboxyl coating allow the visualization of axillary
draining lymph node (ALN) after subcutaneous injection
of a very weak quantity of QDs (20 pmol). Unlike other
tracers, QDs rapidly localize to and remain trapped in the
SLN. A strong fluorescence signal is obtained within a few
minutes lasting at least 24 h as measured with optical fiber
spectrofluorometry, a minimally invasive technique
allowing rapid pre-operative complete procedure. Fluo-
rescence microscopy and chemical extraction confirmed
highly selective QDs accumulation in the ALN corre-
sponding to 2.42% of the injected dose at 60 min after the
injection; the major part remaining at injection site. This
rapid and selective accumulation of QDs in ALN together
with the eventual non-invasive fluorescence detection
offers an exciting opportunity to track lymphatic flow in
real time and guide their nodal dissection after one simple
intraoperative injection.
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